Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03522246 · ClinicalTrials.gov registry record · Phase 3
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
A Phase 3 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by pharmaand.
- Active
- Registry status
- Phase 3
- Development phase
- 1,097
- Enrollment target
- 20
- Study locations
NCT03522246 is a Phase 3 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer that is active but no longer recruiting, run by pharmaand. The registered enrollment target is 1,097 participants, above the 243-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (351% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT03522246, a Phase 3 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, is active but no longer recruiting, sponsored by pharmaand.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,097 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Placebo Oral Tablet
- DRUG Rucaparib
- DRUG Placebo IV Infusion
Study Locations (20)
Florida
- Florida Gynecologic Oncology - Fort Myers
- MD Anderson Cancer Center-Baptist - Jacksonville
- Baptist Health Medical Group Oncology, LLC - Miami
- Florida Hospital - Orlando
Arizona
- Arizona Oncology Associates, PC - HAL - Phoenix
- Arizona Oncology Associates, PC - HOPE - Tucson
- The University of Arizona Cancer Center - Tucson
California
- John Muir Clinical Research Center - Concord
- UCLA Women's Health Clinical Research Unit - Los Angeles
- Kaiser Permanente Northern California - San Francisco
Illinois
- Rush University Medical Center - Chicago
- Dr. Sudarshan K. Sharma, Ltd - Gynecologic Oncology - Hinsdale
- Ferrell-Duncan Clinic - Springfield
Colorado
- University of Colorado Cancer Center - Aurora
- Rocky Mountain Cancer Centers - Lakewood
Georgia
- Northside Hospital - Atlanta
- Augusta University - Augusta
Connecticut
- Yale University - New Haven
Indiana
- Community Health Network - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,097 participants |
| Start Date | 2018-05-14 |
| Est. Completion | 2030-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03522246
The ClinicalTrials.gov registry entry for NCT03522246 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,097 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 243-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (351% higher). The listed sponsor is pharmaand, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.
NCT03522246 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT03522246 about?
NCT03522246 is a clinical study titled "A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy". This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologo...
What is the current status of trial NCT03522246?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,097 participants. The study started on 2018-05-14. Estimated completion is 2030-12-30.
What conditions does trial NCT03522246 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Epithelial Ovarian Cancer, Newly Diagnosed, Primary Peritoneal, FIGO Stage III-IV.
What interventions are being tested in trial NCT03522246?
The interventions under investigation include: Nivolumab (DRUG), Placebo Oral Tablet (DRUG), Rucaparib (DRUG), Placebo IV Infusion (DRUG).
Who is sponsoring clinical trial NCT03522246?
This trial is sponsored by pharmaand, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03522246 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
RECRUITING · Phase 3
-
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.